Among HER2-positive subtype patients, patients with previous female genital/endocrine system cancer history (HR =1.32; 95% CI, 1.08-1.64) and previous other cancers history (HR =1.48; 95% CI, 1.31-1.68) were also associated with a poor prognosis. Here, ERBB2 is linked to cancer.